Today: 17 May 2026
Microsoft stock slides after hours on AI disruption jitters — what’s next for MSFT

Microsoft stock slides after hours on AI disruption jitters — what’s next for MSFT

NEW YORK, Feb 3, 2026, 16:31 (ET) — Trading in after-hours

Microsoft shares fell 2.9% to $411.21 in after-hours trading Tuesday, following a drop during the main session. The stock started the day at $422.00 and fluctuated between $426.50 and $408.62, with roughly 59.9 million shares traded.

The decline followed a broader selloff in software and data-analytics stocks, sparked by new automation tools from Anthropic that reignited the “AI disruption” debate. “Sometimes the market just shoots first and asks questions later,” Mike Archibald of AGF Investments remarked. Jonathan McMullan at Schroders added that investors are “aggressively repricing” as the long-held valuation premium for predictability begins to erode. Reuters

This is crucial now as traders bet on one straightforward thesis: AI investment will boost the largest platforms—and quickly. Once new tools emerge that seem to handle tasks once billed by software, the narrative falters, and the stock ticker reacts accordingly.

Microsoft has faced increased scrutiny since its recent earnings report, which highlighted record AI investments alongside a slowdown in cloud-computing growth. This combination unsettled investors wary of short-term returns.

Piper Sandler stuck with its Overweight rating on Microsoft, signaling expectations that the stock will outperform. The firm held firm on a $600 price target, naming Microsoft a top pick despite cautioning that “seat-compression” might limit valuation multiples in the software sector. TipRanks

Seat compression refers to the risk that customers purchase fewer software “seats”—paid user licenses—as AI tools increase worker productivity. This presents a new challenge for a market accustomed to consistent subscription growth.

The danger is Tuesday’s selloff could linger: investors continue viewing AI as a margin risk for segments of the software stack, even as large firms pour cash into data centers to keep pace. In this environment, any relief rallies may prove fleeting.

The next big test comes with a packed earnings slate from megacap tech, as investors hunt for signs on cloud demand, AI spending, and competitive pressures. “We’re seeing a lot of software companies across the spectrum get hit,” noted Art Hogan of B. Riley Wealth. John Campbell at Allspring Global Investments added that expectations for AI “are really high.” All eyes will be on Alphabet on Wednesday and Amazon on Thursday for insights. Reuters

Stock Market Today

  • Understanding Tax-Loss Harvesting Amid Stock Market Gains
    May 16, 2026, 7:47 PM EDT. Tax-loss harvesting is gaining traction as the stock market surges, offering investors a strategy to offset capital gains by selling investments at a loss. This technique can reduce taxable income and boost after-tax returns. Wall Street professionals are increasingly adopting this approach to optimize portfolios in a high-gain environment. The method involves careful timing and selection of assets to comply with tax regulations while maintaining market positions. As tax considerations grow in importance, investors seek effective strategies like tax-loss harvesting to manage their liabilities amidst fluctuating markets.

Latest articles

Joby Aviation Slides Monday With Air-Taxi in Focus

Joby Aviation Slides Monday With Air-Taxi in Focus

17 May 2026
Joby Aviation shares closed Friday at $10.36, down 2.6% for the day and 4.7% for the week. CEO JoeBen Bevirt-linked trusts sold over 421,000 shares under a preset 10b5-1 plan, filings showed. The stock traded between $10.04 and $10.58 during a volatile week. Broader markets and eVTOL sector peers also declined.
ImmunityBio’s BCG Agreement Puts Monday’s Trading in Focus

ImmunityBio’s BCG Agreement Puts Monday’s Trading in Focus

17 May 2026
ImmunityBio closed at $7.97 Friday, down 2.2% after announcing exclusive U.S. rights to Japan BCG Laboratory’s Tokyo-172 strain for bladder cancer therapy. The Tokyo strain remains investigational in the U.S. and is not FDA-approved. Nasdaq was closed for the weekend; the next trading session is Monday. ImmunityBio’s Q1 product revenue rose to $44.2 million with $380.9 million in cash and securities.
Infleqtion Stock Just Took a Hit After Record Revenue — What Could Move INFQ Next

Infleqtion Stock Just Took a Hit After Record Revenue — What Could Move INFQ Next

17 May 2026
Infleqtion Inc. shares fell 10.95% to $12.44 Friday, capping a rough week for quantum tech stocks. The company reported a first-quarter net loss of $30.3 million on $9.5 million in revenue, with 85% from government contracts. Infleqtion launched a new RF sensing platform and raised its 2026 revenue outlook, but warned of continued operating losses.
Synopsys Shares Dropped for the Week, Looking to May 27 for Direction

Synopsys Shares Dropped for the Week, Looking to May 27 for Direction

17 May 2026
Synopsys shares fell 1.49% Friday to $502.42, ending the week down 2.72% amid a broad tech selloff and news that Coatue Management cut its stake by 54%. The Nasdaq Composite dropped 1.54% Friday, while the Philadelphia semiconductor index slid 4%. Synopsys will report fiscal Q2 results after the market closes on May 27. Wells Fargo and Citigroup raised their price targets for the stock earlier in the week.
Why Freeport-McMoRan Inc (FCX) stock price is up nearly 6% today
Previous Story

Why Freeport-McMoRan Inc (FCX) stock price is up nearly 6% today

Tesla stock barely moves after-hours as $41,990 Model Y AWD debuts — what TSLA traders watch next
Next Story

Tesla stock barely moves after-hours as $41,990 Model Y AWD debuts — what TSLA traders watch next

Go toTop